Discovery of fevipiprant (NVP-QAW039), a potent and selective DP2 receptor antagonist for treatment of asthma

Discovery of fevipiprant (NVP-QAW039), a potent and selective DP2 receptor antagonist for treatment of asthma

Further optimization of an initial DP2 receptor antagonist clinical candidate NVPQAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2- (trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compound 11, NVP-QAW039, fevipiprant), which exhibits improved...

Full description

Bibliographic Details
Main Authors: Sandham, David A., Barker, Lucy, Brown, Lyndon, Brown, Zarin, Budd, David, Charlton, Steven J., Chatterjee, Devnanden, Cox, Brian, Dubois, Gerald, Duggan, Nicholas, Hall, Edward, Hatto, Julia, Maas, Janet, Manini, Jodie, Profit, Rachael, Riddy, Darren, Ritchie, Catherine, Sohal, Bindi, Shaw, Duncan, Stringer, Rowan, Sykes, David A., Thomas, Matthew, Turner, Katherine L., Watson, Simon J., West, Ryan, Willard, Elisabeth, Williams, Gareth, Willis, Jennifer
Format: Article
Published: American Chemical Society 2017
Subjects:
DP2 receptor antagonist
severe asthma
clinical candidate
Online Access:https://eprints.nottingham.ac.uk/44096/

Internet

https://eprints.nottingham.ac.uk/44096/

Similar Items